1. Long-term outcomes of myeloablation and autologous transplantation of relapsed acute myeloid leukemia in second remission: a British Society of Blood and Marrow Transplantation registry study. Chantry AD, Snowden JA, Craddock C, Peggs K, Roddie C, Craig JI, Orchard K, Towlson KE, Pearce RM, Marks DI; BSBMT Clinical Trials Committee. Biol Blood Marrow Transplant. 2006 Dec;12(12):1310-7.
2. The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study. Bird JM, Fuge R, Sirohi B, Apperley JF, Hunter A, Snowden J, Mahendra P, Milligan D, Byrne J, Littlewood T, Fegan C, McQuaker G, Pagliuca A, Johnson P, Rahemtulla A, Morris C, Marks DI; British Society of Blood and Marrow Transplantation. Br J Haematol. 2006 Aug;134(4):385-90. Epub 2006 Jul 5.
3. The outcome of sibling and unrelated donor allogeneic stem cell transplantation in adult patients with acute myeloid leukemia in first remission who were initially refractory to first induction chemotherapy. Cook G, Clark RE, Crawley C, Mackinnon S, Russell N, Thomson K, Pearce RM, Towlson K, Marks DI. Biol Blood Marrow Transplant. 2006 Mar;12(3):293-300.
4. Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study.
Delgado J, Thomson K, Russell N, Ewing J, Stewart W, Cook G, Devereux S, Lovell R, Chopra R, Marks DI, Mackinnon S, Milligan DW; British Society of Blood and Marrow Transplantation. Blood. 2006 Feb 15;107(4):1724-30. Epub 2005 Oct 20.